A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Impact of CLB101TM️ on Gut Health in Healthy, Overweight Individuals

NCT07336615 · clinicaltrials.gov ↗

NA

Phase

ENROLLING_BY_INVITATION

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastrointestinal
Overweight , Obesity

Interventions

DIETARY_SUPPLEMENT: CLB101™️
OTHER: Placebo
DIETARY_SUPPLEMENT: CLB101™️
OTHER: Placebo control

Sponsor

ClostraBio Inc.